BenzingaOctober 16, 2026 at 4:57 AM NY11 Days Ago
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
